In non‐alcoholic fatty liver disease, USP14 stabilises HSP90AA1 through deubiquitination, leading to increased levels of CYP2E1 and further exacerbating disease progression [32]. This evidence concerns the gene CYP2E1 and metabolic dysfunction-associated steatotic liver disease.